How should systemic vascular resistance (SVR) and pulmonary vascular resistance (PVR) values be interpreted and managed in adult patients?

Interpreting SVR and PVR Values in Adult Patients

Systemic vascular resistance (SVR) should be interpreted as a marker of vascular tone with normal values ranging from 800-1200 dyne·sec/cm⁵ (or 1600-2400 dyne·sec/cm⁵·m² when indexed), while pulmonary vascular resistance (PVR) >2 Wood Units now defines clinically significant pulmonary vascular disease requiring close monitoring and potential intervention.

Understanding Normal and Abnormal Values

SVR Interpretation

• Normal SVR: 800-1200 dyne·sec/cm⁵ (or SVRi 1600-2400 dyne·sec/cm⁵·m² when indexed)
• Low SVR state: SVRi <1800 dyne·sec/cm⁵·m² at two consecutive measurements 1
• Critical consideration: SVR calculations must account for blood viscosity, particularly during hypothermia or hemodilution, as uncorrected values significantly underestimate true vascular resistance 2

PVR Interpretation

The hemodynamic definition of pulmonary hypertension has been fundamentally revised 3:

• Normal PVR: ≤2 Wood Units (WU)
• Elevated PVR: >2 WU now defines pre-capillary pulmonary vascular disease 4, 3
• Mean pulmonary artery pressure (mPAP): >20 mmHg (lowered from ≥25 mmHg) defines pulmonary hypertension 3

The combination of mPAP >20 mmHg AND PVR >2 WU is now required to diagnose pre-capillary pulmonary hypertension, emphasizing that elevated pressure alone is insufficient 4, 3.

Clinical Significance and Prognostic Implications

PVR as a Mortality Predictor

PVR elevation carries independent prognostic significance even when mPAP is normal. In patients with interstitial lung disease, PVR >2 WU was associated with significantly higher mortality (HR 1.61,95% CI 1.28-2.02, p<0.0001) even when mPAP remained ≤20 mmHg 5. Critically, PVR predicted mortality while mPAP did not (HR 1.37 vs 0.98, respectively) 5.

Pulmonary Capillary Wedge Pressure (PCWP) Integration

PCWP must be incorporated when interpreting the PVR-compliance relationship, particularly in low-resistance states. In isolated post-capillary pulmonary hypertension, adjusting for PCWP improved model fit from R² 0.725 to 0.919 6. This adjustment is essential for accurate assessment of right ventricular afterload.

Management Algorithm Based on Values

For Elevated PVR (>2 WU)

In congenital heart disease with pulmonary arterial hypertension 7:

1. Confirm diagnosis: Cardiac catheterization remains the gold standard—echocardiography alone is insufficient for accurate PVR determination
2. Risk stratification: Identify predictors including defect size (ASD >2 cm, VSD >1 cm), Qp:Qs ≥3, PASP >40 mmHg, older age at repair, female sex
3. Treatment initiation:
   • Bosentan is beneficial in symptomatic Eisenmenger syndrome with ASD or VSD (Class I, Level A recommendation) 7
   • Combination therapy with bosentan and PDE-5 inhibitors is reasonable if monotherapy fails (Class IIa, Level B-R) 7

In critical care settings with pulmonary vascular dysfunction 8:

1. Volume management: Avoid aggressive volume loading as it may worsen RV performance (weak recommendation, very-low-quality evidence)
2. Vasopressor support: Low-dose norepinephrine is effective (weak recommendation, low-quality evidence)
3. Inotropic support: Low-dose dobutamine improves RV function (weak recommendation, low-moderate quality evidence)
4. Pulmonary vasodilators: Strongly recommended (moderate-quality evidence) to reduce PVR and improve RV function, with inhaled agents preferred over systemic to minimize hypotension 8
5. Phosphodiesterase type III inhibitors: Reduce PVR and improve RV function but frequently cause hypotension (strong recommendation, moderate-quality evidence) 8

For Low SVR (<1800 dyne·sec/cm⁵·m²)

Low SVR represents systemic inflammatory response and requires specific management 1:

• Occurs in 44% of post-cardiopulmonary bypass patients 1
• Hemodynamic pattern: Initial sustained increase in cardiac index and central venous pressure precedes the decrease in mean arterial pressure (maximal at 8 hours postoperatively)
• Management priority: Vasopressors to restore vascular tone are preferred over volume loading to further increase cardiac index 1
• Risk factors: Longer cross-clamp times, male sex, lower postoperative platelet counts

Critical Pitfalls to Avoid

1. Do not rely on echocardiography alone for PVR assessment—cardiac catheterization with careful hemodynamic measurements is fundamental to accurate diagnosis 7, 4

2. Do not ignore mildly elevated PVR (2-3 WU): While no evidence-based treatments exist for this range, these patients require close monitoring as even modest residual PAH substantially determines intermediate and longer-term outcomes 7, 3

3. Do not overlook viscosity corrections when interpreting SVR, particularly during hypothermia or hemodilution—uncorrected values significantly underestimate true vascular resistance 2

4. Do not assume mPAP 21-24 mmHg is benign: This range is associated with increased morbidity and mortality compared to normal mPAP, requiring close monitoring even though approved PAH treatments have not been studied in this population 9, 3

5. In congenital heart disease, do not close defects when PVR is markedly elevated with small defects (VSD <1 cm, ASD <2 cm)—the clinical picture resembles idiopathic PAH and closure is contraindicated 4

Monitoring Requirements

For patients with ACHD and pulmonary hypertension 7:

• Baseline cardiac catheterization is mandatory
• Serial catheterization as clinically indicated
• Multidisciplinary care involving both ACHD and pulmonary vascular disease specialists is necessary for optimal outcomes

For patients with mPAP 21-24 mmHg or PVR 2-3 WU: Close clinical monitoring is essential, with repeat hemodynamic assessment if symptoms progress, as this represents an at-risk population without established treatment protocols 3.